Related Experiment Video
Updated: Jun 6, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Mast cell sarcoma with KIT p.D816V mutation and concurrent systemic mastocytosis
Nicholas Collins1, Nicholas Willard1, Zenggang Pan2
1Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, USA.
Mast cell sarcoma (MCS) is a rare cancer. This report details a unique case of MCS with concurrent systemic mastocytosis (SM), both featuring the KIT p.D816V mutation, suggesting a potential progression pathway.
Area of Science:
- Hematology
- Oncology
- Molecular Pathology
Background:
- Mast cell sarcoma (MCS) is an aggressive, rare mastocytosis variant.
- MCS typically arises de novo, lacking established molecular drivers or precursor lesions.
- Rare instances suggest a possible progression from systemic mastocytosis (SM) or cutaneous mastocytosis (CM) to MCS.
More Related Videos
07:21Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
09:08Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
Related Concept Videos
Abnormal Proliferation
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...